 WINNIPEG, May 10, 2021 PRNewswire - Medicure Inc. Medicure or the Company TSXV: MPH OTC: MCUJF, a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended March 31, 2021. Quarter Ended March 31, 2021 Highlights: Recorded total net revenue of 4.9 million during the quarter ended March 31, 2021 compared to 3.0 million for the quarter ended March 31, 2020 and; Recorded total net revenue from the sale of AGGRASTAT of 2.6 million during the quarter ended March 31, 2021 compared to 2.7 million for the quarter ended March 31, 2020 and; Diversified product portfolio with revenues from the Marley Drug business of 2.1 million and ZYPITAMAG revenues of 161,000 during the quarter ended March 31, 2021 and; Adjusted earnings before interest, taxes, depreciation and amortization EBITDA1 for the quarter ended March 31, 2021 was 31,000 compared to adjusted EBITDA of negative 1.3 million for the quarter ended March 31, 2020 and; Net loss for the quarter ended March 31, 2021 was 1.0 million compared to 1.5 million for the quarter ended March 31, 2020. 